Skip to main page content

• HOME
• Current Issue
• Archive
• Alerts
• About ASM
• Contact us
• Tech Support
• Journals.ASM.org

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Murayama, S. Y. Search for Related Content PubMed PubMed Citation Articles by Murayama, S. Y.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2009, p. 2650-2653, Vol. 53, No. 6
0066-4804/09/$08.00+0     doi:10.1128/AAC.01716-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Capsular Type and Antibiotic Resistance in Streptococcus agalactiae Isolates from Patients, Ranging from Newborns to the Elderly, with Invasive Infections

Somay Yamagata Murayama,¹ Chizuko Seki,¹ Hiroshi Sakata,² Katsuhiko Sunaoshi,¹ Eiichi Nakayama,¹ Satoshi Iwata,³ Keisuke Sunakawa,⁴ Kimiko Ubukata,^1* and the Invasive Streptococcal Disease Working Group

Laboratory of Molecular Epidemiology for Infectious Agents, Graduate School of Infection Control Sciences & Kitasato Institute for Life Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan,¹ Department of Pediatrics, Asahikawa-Kosei General Hospital, 1-24 Asahikawa City, Hokkaido 078-8211, Japan,² Department of Pediatrics, National Hospital Organization Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo 152-8902, Japan,³ Laboratory of Infectious Diseases, Kitasato Institute for Life Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan⁴

Received 25 December 2008/ Returned for modification 15 February 2009/ Accepted 21 March 2009

Top ABSTRACT INTRODUCTION REFERENCES

 
Streptococcus agalactiae isolates (n = 189) from patients with invasive infections were analyzed for capsular type by PCR, for antimicrobial susceptibility, and for the presence of resistance genes. In contrast to the predominance of capsular type III in children, types Ib and V were most common among adults. All 45 levofloxacin-resistant strains had two amino acid substitutions, Ser₈₁Leu in the gyrA gene and Ser₇₉Phe in the parC gene, and showed similar pulsed-field gel electrophoresis patterns.

Top ABSTRACT INTRODUCTION REFERENCES

 
Streptococcus agalactiae (a group B streptococcus [GBS]) is the main microorganism causing meningitis and sepsis in infants and also sepsis in nonpregnant adults (12, 14).

GBS infection in infants is classified as early onset, occurring in newborns within the first week of life, or late onset, developing in infants more than 1 week old, with most infections arising in the first 3 months and only extremely rarely in older infants (18). In the 1970s, morbidity and mortality from these GBS infections were high (3, 4, 9). In 1996, however, recommendations for the prevention of perinatal GBS infection were issued by the American College of Obstetricians and Gynecologists (2), the Centers for Disease Control and Prevention (7), and later also the American Academy of Pediatrics (1). As a result, preventive efforts increased and the incidence of early-onset disease decreased substantially (6, 23). A more detailed revised guideline, based on prenatal bacterial cultures and epidemiologic studies, was recommended in 2002 (17).

Recently, Phares et al. (15) reported on a 7-year epidemiologic survey of invasive GBS disease in the United States that demonstrated a significant decline in the incidence of early-onset disease in infants, contrasting with an increase in GBS disease among adults 65 years old.

In the present paper, we describe details concerning patient age, disease, and underlying diseases associated with invasive GBS infection, as well as the capsular types, antimicrobial susceptibilities, and resistance genes of isolates in Japan.

Between August 2006 and July 2007, our laboratory received 189 GBS strains from the bacteriologic laboratories of 97 medical institutions participating in the Invasive Streptococcal Disease Working Group at the 19th Annual Meeting of the Japanese Society for Clinical Microbiology. All isolates were from sterile sites: blood (n = 124), cerebrospinal fluid (n = 54), pustule fluid (n = 7), joint fluid (n = 3), and tissue (n = 1).

To identify the capsular type of GBS by PCR, we used nine sets of primers from types Ia to VIII as reported by Poyart et al. (16). We also applied our newly designed dltS primers for the identification of GBS (Table 1).

View this table: [in this window] [in a new window]

TABLE 1. Primers for PCR and sequencing for FQ resistance in S. agalactiae

One colony was picked up from each agar plate and placed in 30 µl of lysis solution containing 1 U of mutanolysin. The lytic reaction was carried out for 20 min at 60°C, followed by 5 min at 94°C. The lysate was added to each of five tubes containing PCR mixtures for individual capsular types: types Ia and Ib in tube A, types II and III in tube B, types IV and dltS in tube C, types V and VII in tube D, and types VI and VIII in tube E. The reaction mixture (25 µl) consisted of 20 pmol of each primer, 0.625 U of AmpliTaq Gold polymerase (Applied Biosystems, Tokyo, Japan), 2.5 µl of 10x PCR Gold buffer, 2.5 µl of 25 mM MgCl₂, 2 µl of a 2 mM deoxynucleotide triphosphate mixture, and 16.875 µl of DNase- and RNase-free distilled water. DNA amplification was carried out with 40 cycles of 94°C for 1 min, 53°C for 2 min, and 72°C for 2 min.

We measured the antimicrobial susceptibilities of GBS strains to 14 antibiotics including oral and parenteral agents by agar plate dilution methods using blood agar.

Three genes for macrolide (ML) resistance, erm(A), erm(B), and mef(A), were identified with the three sets of primers and PCR conditions described previously (21).

To identify fluoroquinolone (FQ) resistance, four sets of primers were designed based on the sequences of the gyrA, gyrB, parC, and parE genes (Table 1). The PCR mixture (50 µl) consisted of 20 pmol of each primer, 0.625 U of TaKaRa Ex Taq polymerase (Takara Bio, Kyoto, Japan), 5 µl of 10x Ex Taq buffer, 4 µl of the 2.5 mM deoxynucleotide triphosphate mixture, and 38.25 µl of DNase- and RNase-free distilled water. Amplified and purified DNA samples were sequenced with a BigDye Terminator cycle sequencing kit (version 3.1; Applied Biosystems, Foster City, CA). The pbp2x gene encoding the PBP2X enzyme, which mediates septum formation during cell wall synthesis, was also sequenced with primers reported previously (11).

We performed pulsed-field gel electrophoresis (PFGE) on the 45 GBS strains determined to have FQ resistance according to mutations in the gyrA and parC genes. Plug-embedded GBS cells were lysed with lysozyme (5,000 U/3 ml) and mutanolysin (20 U/ml) at 50°C for 3 h by a modification described previously (5, 8). Chromosomal DNA was digested at 37°C for 18 h with ApaI (100 U/ml). PFGE was performed with 1% agarose and 0.5x TBE buffer (1x TBE is 90 mM Tris base, 88 mM boric acid, and 2 mM EDTA) at pulse times of 2.91 to 17.33 s, at an angle of 120°, at 6.0 V/cm, and at 14°C for 20 h with the CHEF Mapper (Bio-Rad Laboratories, Hercules, CA).

Table 2 shows relationships between capsular types of GBS pathogens and diagnoses, separately considering children 17 years old (n = 65) and adults (n = 124). Diseases were classified into meningitis, sepsis, and other infection groups. In children including newborns (10.8%) with early-onset disease and neonates (70.8%) with late-onset disease, capsular type III predominated at 67.7%, with small numbers of other types. Among adults, those at least 50 years old accounted for 83.1% of the cases; capsular type Ib predominated at 31.5%, followed by V (18.5%), II (12.1%), and III (12.1%). In addition to sepsis (75.0%), a variety of diseases were noted: cellulitis, arthritis, necrotizing fasciitis, meningitis, and bacterial endocarditis. Importantly, 88.7% of the affected adults had underlying disease such as diabetes, liver dysfunction, or immune compromise. Instances of death and neurologic sequelae included one of each among children, and eight (6.4%) and two (1.6%) among adults, respectively.

View this table: [in this window] [in a new window]

TABLE 2. Correlation of capsular types of strains with 189 invasive GBS infections

Table 3 shows the MIC ranges and MICs for 50 and 90% of the strains tested (MIC₅₀, and MIC₉₀, respectively) of oral and intravenous antibiotics for GBS strains. The MIC range of β-lactam agents was narrow, and penicillin-resistant strains were not recognized. Notably, in a strain where cefotiam susceptibility was reduced to 2 µg/ml, four amino acid substitutions, Gly₃₉₈ to Ala, Gln₄₁₂ to Leu, His₄₃₈ to Tyr, and Ile₆₀₀ to Val, were identified in the pbp2x gene.

View this table: [in this window] [in a new window]

TABLE 3. Susceptibilities of 189 S. agalactiae isolates to 14 antimicrobial agents

Table 4 shows relationships between ML and FQ resistance and capsular type, separately considering children and adults. Of 23 strains showing ML resistance (12.2%), 3 possessed the erm(A) gene and 20 possessed the erm(B) gene. The M type was not recognized. ML-resistant strains detected in both children and adults were mostly type III, but a few strains showed other capsular types.

View this table: [in this window] [in a new window]

TABLE 4. Correlation of capsular types with FQ and ML resistance

In 45 strains showing high levofloxacin resistance (23.8%), two amino acid substitutions, Ser₈₁ to Leu encoded by the gyrA gene and Ser₇₉ to Phe encoded by the parC gene, were identified simultaneously. The capsular type of these strains, including six isolated from children, was predominately Ib, which was observed in 34 strains; other types (II, III, and VI) were each seen in a few strains.

The PFGE patterns of 45 FQ-resistant strains are shown in Fig. 1. These strains included 40 strains of type Ib and 5 strains representing other types. All type Ib strains showed highly homologous restriction patterns that differed clearly from those of type II or III strains.

View larger version (53K): [in this window] [in a new window]

FIG. 1. PFGE patterns of levofloxacin-resistant S. agalactiae isolates. Each DNA sample was digested with the ApaI restriction enzyme. Lanes M, lambda ladder.

In Japan, the proportion of the elderly population with underlying diseases has increased rapidly. As a consequence, invasive infections caused not only by GBS, but also S. dysgalactiae subsp. equisimilis and S. pneumoniae, are expected to increase gradually and to become serious problems (19, 20).

The capsular type in isolates from newborns was mostly type III, in agreement with previous results. In most cases involving adults at least 50 years old, however, type Ib was predominant, followed by type V. These findings differ from previous epidemiologic data from the United States; the reason for this disparity is not known.

The percentage of ML resistance was not particularly high compared with that in other countries. Much attention has been drawn to the emergence of GBS with reduced susceptibility to penicillin and cephalosporin antibiotics arising from mutations in the pbp2x gene (11). One of our collected strains had mutations of the pbp2x gene; this was a type III strain with multiple-antibiotic resistance to ML and FQ. FQ-resistant strains have been reported previously (10, 13, 22) but at extremely low rates. In our results, however, strains resistant only to FQ accounted for 23.8% of the isolates, and most of these were type Ib. FQ-resistant GBS from newborns, who had not been exposed to the agent, showed a PFGE pattern very similar to type Ib from adults. The observations suggest that a single clone acquired FQ resistance and spread rapidly throughout Japan.

Antimicrobial use in Japan favors oral cephalosporins as the drugs of first choice for children, while oral FQ and ML, as well as cephalosporins, are often prescribed for adults. Notably, the size of individual doses of antimicrobials typically is small in Japan compared with that in other countries. These factors will expand the mutant selection window for many pathogens, including GBS, and thus may cause an increase in resistant microorganisms.

To control the emergence of resistant organisms, continuous molecular epidemiologic surveillance for pathogens is needed.

 
This study was planned at one of the workshops at the 19th Annual Meeting of the Japanese Society for Clinical Microbiology, aiming to determine the molecular epidemiology and clarify background factors in invasive S. agalactiae infection. We express our thanks to staff members at all participating institutions.

This work was supported by a grant under the category Research Project for Emerging and Re-emerging Infectious Diseases (H-19-002) from the Japanese Ministry of Health, Labor and Welfare.

 
* Corresponding author. Mailing address: Laboratory of Molecular Epidemiology for Infectious Agents, Graduate School of Infection Control Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan. Phone: 81-3-5791-6385. Fax: 81-3-5791-6386. E-mail: ubukatak{at}lisci.kitasato-u.ac.jp

Published ahead of print on 30 March 2009.

Top ABSTRACT INTRODUCTION REFERENCES

 

1
1. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. 1997. Revised guidelines for prevention of early-onset group B streptococcal (GBS) infection. Pediatrics 99:489-496.[Abstract/Free Full Text]
2
2. American College of Obstetrics and Gynecologists Committee on Obstetric Practice. 1996. ACOG committee opinion. Prevention of early-onset group B streptococcal disease in newborns. Number 173-June 1996. Int. J. Gynaecol. Obstet. 54:197-205.[CrossRef][Medline]
3
3. Baker, C. J., F. F. Barrett, R. C. Gordon, and M. D. Yow. 1973. Suppurative meningitis due to streptococci of Lancefield group B: a study of 33 infants. J. Pediatr. 82:724-729.[CrossRef][Medline]
4
4. Barton, L. L., R. D. Feigin, and R. Lins. 1973. Group B beta hemolytic streptococcal meningitis in infants. J. Pediatr. 82:719-723.[CrossRef][Medline]
5
5. Benson, J. A., and P. Ferrieri. 2001. Rapid pulsed-field gel electrophoresis method for group B streptococcus isolates. J. Clin. Microbiol. 39:3006-3008.[Abstract/Free Full Text]
6
6. Centers for Disease Control and Prevention. 2000. From the Centers for Disease Control and Prevention: early-onset group B streptococcal disease—United States, 1998-1999. JAMA 284:1508-1510.[Free Full Text]
7
7. Centers for Disease Control and Prevention. 1996. Prevention of perinatal group B streptococcal disease: a public health perspective. MMWR Recommend. Rep. 45:1-24.
8
8. Chiba, N., R. Kobayashi, K. Hasegawa, M. Morozumi, E. Nakayama, T. Tajima, S. Iwata, and K. Ubukata. 2005. Antibiotic susceptibility according to genotype of penicillin-binding protein and macrolide resistance genes, and serotype of Streptococcus pneumoniae isolates from community-acquired pneumonia in children. J. Antimicrob. Chemother. 56:756-760.[Abstract/Free Full Text]
9
9. Franciosi, R. A., J. D. Knostman, and R. A. Zimmerman. 1973. Group B streptococcal neonatal and infant infections. J. Pediatr. 82:707-718.[CrossRef][Medline]
10
10. Kawamura, Y., H. Fujiwara, N. Mishima, Y. Tanaka, A. Tanimoto, S. Ikawa, Y. Itoh, and T. Ezaki. 2003. First Streptococcus agalactiae isolates highly resistant to quinolones, with point mutations in gyrA and parC. Antimicrob. Agents Chemother. 47:3605-3609.[Abstract/Free Full Text]
11
11. Kimura, K., S. Suzuki, J. Wachino, H. Kurokawa, K. Yamane, N. Shibata, N. Nagano, H. Kato, K. Shibayama, and Y. Arakawa. 2008. First molecular characterization of group B streptococci with reduced penicillin susceptibility. Antimicrob. Agents Chemother. 52:2890-2897.[Abstract/Free Full Text]
12
12. Lindahl, G., M. Stalhammar-Carlemalm, and T. Areschoug. 2005. Surface proteins of Streptococcus agalactiae and related proteins in other bacterial pathogens. Clin. Microbiol. Rev. 18:102-127.[Abstract/Free Full Text]
13
13. Miró, E., M. Rebollo, A. Rivera, M. T. Alvarez, F. Navarro, B. Mirelis, and P. Coll. 2006. Streptococcus agalactiae highly resistant to fluoroquinolones. Enferm. Infecc. Microbiol. Clin. 24:562-563.[CrossRef][Medline]
14
14. Nizet, V., and C. E. Rubens. 2006. Pathogenic mechanisms and virulence factors of group B streptococci, p. 152-168. In V. A. Fischetti, R. P. Novick, J. J. Ferretti, D. A. Portnoy, and J. I. Rood (ed.), Gram-positive pathogens, 2nd ed. ASM press, Washington, DC.
15
15. Phares, C. R., R. Lynfield, M. M. Farley, J. Mohle-Boetani, L. H. Harrison, S. Petit, A. S. Craig, W. Schaffner, S. M. Zansky, K. Gershman, K. R. Stefonek, B. A. Albanese, E. R. Zell, A. Schuchat, and S. J. Schrag. 2008. Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA 299:2056-2065.[Abstract/Free Full Text]
16
16. Poyart, C., A. Tazi, H. Reglier-Poupet, A. Billoet, N. Tavares, J. Raymond, and P. Trieu-Cuot. 2007. Multiplex PCR assay for rapid and accurate capsular typing of group B streptococci. J. Clin. Microbiol. 45:1985-1988.[Abstract/Free Full Text]
17
17. Schrag, S., R. Gorwitz, K. Fultz-Butts, and A. Schuchat. 2002. Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. MMWR Recommend. Rep. 51:1-22.
18
18. Schuchat, A. 1998. Epidemiology of group B streptococcal disease in the United States: shifting paradigms. Clin. Microbiol. Rev. 11:497-513.[Abstract/Free Full Text]
19
19. Ubukata, K., N. Chiba, K. Hasegawa, R. Kobayashi, S. Iwata, and K. Sunakawa. 2004. Antibiotic susceptibility in relation to penicillin-binding protein genes and serotype distribution of Streptococcus pneumoniae strains responsible for meningitis in Japan, 1999 to 2002. Antimicrob. Agents Chemother. 48:1488-1494.[Abstract/Free Full Text]
20
20. Ubukata, K., K. Sunaoshi, R. Kobayashi, and K. Okuzumi. 2006. Large-scale questionnaire surveillance concerning invasive infections with group C and G streptococci. Kansenshogaku Zasshi 80:480-487.[Medline]
21
21. Wajima, T., S. Y. Murayama, K. Sunaoshi, E. Nakayama, K. Sunakawa, and K. Ubukata. 2008. Distribution of emm type and antibiotic susceptibility of group A streptococci causing invasive and noninvasive disease. J. Med. Microbiol. 57:1383-1388.[Abstract/Free Full Text]
22
22. Wehbeh, W., R. Rojas-Diaz, X. Li, N. Mariano, L. Grenner, S. Segal-Maurer, B. Tommasulo, K. Drlica, C. Urban, and J. J. Rahal. 2005. Fluoroquinolone-resistant Streptococcus agalactiae: epidemiology and mechanism of resistance. Antimicrob. Agents Chemother. 49:2495-2497.[Abstract/Free Full Text]
23
23. Zangwill, K. M., A. Schuchat, and J. D. Wenger. 1992. Group B streptococcal disease in the United States, 1990: report from a multistate active surveillance system. MMWR Surveill. Summ. 41:25-32.

---

Antimicrobial Agents and Chemotherapy, June 2009, p. 2650-2653, Vol. 53, No. 6
0066-4804/09/$08.00+0     doi:10.1128/AAC.01716-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Sunaoshi, K., Murayama, S. Y., Adachi, K., Yagoshi, M., Okuzumi, K., Chiba, N., Morozumi, M., Ubukata, K. (2010). Molecular emm genotyping and antibiotic susceptibility of Streptococcus dysgalactiae subsp. equisimilis isolated from invasive and non-invasive infections. J Med Microbiol 59: 82-88 [Abstract] [Full Text]  

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Murayama, S. Y. Search for Related Content PubMed PubMed Citation Articles by Murayama, S. Y.